Breast Cancer Recurrent Clinical Trial
Official title:
:Single-arm, Phase II Clinical Trial of Utidelone Capsule Plus Capecitabine (CAP) in Patients With Metastatic Breast Cancer
This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients. This study was a single-arm, phase II study of patients with recurrent or metastatic HER2-negative breast cancer who had previously received chemotherapy regimens containing taxanes and/or anthracyclines were treated with a combination of utidelone capsules and capecitabine. The main objective was to explore the efficacy and safety of the combined regimen.
Patients with recurrent or metastatic HER2 negative breast cancer who have previously received chemotherapy containing taxanes and/or anthracyclines will receive combined treatment with utidelone capsule and capecitabine. Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14. Every 21 days is a cycle until disease progression, intolerable adverse events occur, subjects voluntarily withdraw, or the researcher determines that medication must be terminated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05301530 -
Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients.
|
Phase 1 | |
| Recruiting |
NCT05592938 -
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
|
N/A | |
| Completed |
NCT04330339 -
Prolonged Nightly Fasting in Breast Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT02915445 -
EpCAM CAR-T for Treatment of Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02844335 -
Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05464082 -
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
|
Phase 2 | |
| Completed |
NCT05301010 -
Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients
|
Phase 3 | |
| Recruiting |
NCT05730608 -
18F-FDG PET/CT Imaging for Breast Cancer
|
N/A | |
| Completed |
NCT01552655 -
Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT
|
N/A | |
| Not yet recruiting |
NCT05406661 -
Registry of Local Recurrences After Breast-conserving Surgery
|
||
| Recruiting |
NCT03820830 -
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
|
Phase 3 | |
| Completed |
NCT02248571 -
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
|
Phase 4 | |
| Recruiting |
NCT02947061 -
S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer
|
Phase 2 |